Debio 4326-301: An open-label, single-arm, multi-center, Phase 3 study on the efficacy, safety, and pharmacokinetics of Debio 4326, a triptorelin 12-month formulation, in pediatric participants who are receiving gonadotropin-releasing hormone agonist therapy for central precocious puberty
Primary Objective
study on the efficacy, safety and pharmacokinetics of Debio 4326 in pediatric participants who are receiving gonadotropin-releasing hormone agonist therapy for central precocious puberty
Description
Interventional
Details
Age
Child
Eligibility
Central precocious puberty
Locations
Childrens Hospital Colorado
Principal Investigator
Natalie Nokoff
Study ID
Protocol Number: 23-2241
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers